1. Thakkar, R, Sareddy, G R, Zhang, Q, Vadlamudi, R K, Brann, D. . PELP1: a key mediator of oestrogen signalling and actions in the brain. In Journal of neuroendocrinology, 30, . doi:10.1111/jne.12484. https://pubmed.ncbi.nlm.nih.gov/28485080/
2. Sareddy, Gangadhara Reddy, Vadlamudi, Ratna K. 2016. PELP1: Structure, biological function and clinical significance. In Gene, 585, 128-134. doi:10.1016/j.gene.2016.03.017. https://pubmed.ncbi.nlm.nih.gov/26997260/
3. Altwegg, Kristin A, Pratap, Uday P, Liu, Zexuan, Rao, Manjeet K, Vadlamudi, Ratna K. 2023. Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34. In Breast cancer research and treatment, 200, 151-162. doi:10.1007/s10549-023-06958-4. https://pubmed.ncbi.nlm.nih.gov/37199805/
4. Luo, Yiliao, Li, Mengxing, Pratap, Uday P, Sareddy, Gangadhara R, Vadlamudi, Ratna K. 2019. PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway. In Molecular carcinogenesis, 59, 281-292. doi:10.1002/mc.23152. https://pubmed.ncbi.nlm.nih.gov/31872914/
5. Brann, Darrell W, Zhang, Quan-Guang, Wang, Rui-Min, Mahesh, Virendra B, Vadlamudi, Ratna K. 2008. PELP1--a novel estrogen receptor-interacting protein. In Molecular and cellular endocrinology, 290, 2-7. doi:10.1016/j.mce.2008.04.019. https://pubmed.ncbi.nlm.nih.gov/18571832/
6. Yang, Xue, Liu, Zexuan, Tang, Weiwei, Viswanadhapalli, Suryavathi, Vadlamudi, Ratna K. 2023. PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. In Molecular oncology, 18, 2136-2156. doi:10.1002/1878-0261.13539. https://pubmed.ncbi.nlm.nih.gov/37853941/
7. Sareddy, Gangadhara R, Pratap, Uday P, Viswanadhapalli, Suryavathi, Brann, Darrell W, Vadlamudi, Ratna K. 2019. PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling. In Neuro-oncology advances, 1, vdz042. doi:10.1093/noajnl/vdz042. https://pubmed.ncbi.nlm.nih.gov/32309805/